Velogen 250 mg (Capsule)

Indications

• Treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria
• Upper respiratory tract infections
• Lower respiratory tract infections
• Urinary tract infections
• Skin and soft tissue infections
• Susceptible microorganisms

Pharmacology

• Semisynthetic broad spectrum bactericidal antibiotic
• Active against both gram-positive and gram-negative microorganisms
• Inhibits cross-linking process of peptidoglycan in bacteria cell wall

Dosage & Administration

• For oral administration in adults and children
• Dosage based on infection type and severity
• Injectable administration for adults and children
• Dosage adjustment in renal impairment

Interaction

• Risk of kidney damage with nephrotoxic drugs
• Enhanced renal toxicity with diuretics and probenecid

Contraindications

• Hypersensitivity to cephalosporins

Side Effects

• Gastro-intestinal disturbances
• Hypersensitivity phenomena
• Skin reactions
• Blood and lymphatic system disorders
• Immune system disorders
• Psychiatric disorders
• Nervous system disorders
• Hepatobiliary disorders
• Renal and urinary disorders
• Elevation of blood urea nitrogen and serum creatinine

Pregnancy & Lactation

• Safety not established in pregnancy
• Excreted in breast milk
• Caution in lactating mothers

Precautions & Warnings

• Risk of superinfection with prolonged use
• Administer with care to patients hypersensitive to penicillins
• Cephalosporin antibiotics may cause a positive result in Coombs’ testing
• May cause false positive urine glucose result
• Dosage adjustment in renal impairment
• Contains lactose

Use in Special Populations

• Doses recommended for patients with renal impairment and on haemodialysis
• Higher doses may be required for chronic or severe infections
• Monitoring required for chronic urinary tract infections

Overdose Effects

• Non-specific symptoms of nausea, vomiting, and diarrhoea
• Mainly supportive treatment
• Gastric lavage may be necessary

Therapeutic Class

• First generation Cephalosporins

Storage Conditions

• Freshly prepared suspension
• Reconstituted suspension expiry within 7-14 days
• Injection solutions expiry within 2 hours if at room temperature
• Solutions retain potency for 12 hours at 5°C
• Must be dispensed only on prescription

Usability

• Oral administration
• Injectable administration

Age Group

• Adults
• Children
• Elderly

Organism Susceptibility

• Staphylococci
• Streptococci
• Escherichia coli
• Klebsiella spp
• Proteus mirabilis
• Haemophilus influenza
• Shigella spp
• Salmonella spp
• Neisseria spp

Respiratory Infections

• Sinusitis
• Pharyngitis
• Tonsillitis
• Bronchitis
• Pneumonia

Urinary Tract Infections

• Cystitis
• Urethritis
• Pyelonephritis

Soft Tissue Infections

• Abscess
• Cellulitis
• Furunculosis
• Impetigo

Renal Impairment

• Dosage adjustment required

Superinfection Risk

• Prolonged use may result in development of superinfection

Blood Disorders

• Thrombocytopenia
• Leucopenia
• Agranulocytosis
• Aplastic anaemia
• Haemolytic anaemia

Hypersensitivity Reactions

• Urticaria
• Skin rashes
• Joint pains
• Oedema

Nervous System Effects

• Dizziness
• Nervousness
• Headache

Hepatobiliary Effects

• Liver enzyme disturbances
• Transient hepatitis
• Cholestatic jaundice

Renal Disorders

• Reversible interstitial nephritis

Teratogenicity

• Not demonstrated in animal studies

Breastfeeding Caution

• Excreted in breast milk

Machinery Caution

• May cause dizziness, caution advised

Cephalosporin Cross-Sensitivity

• Risk of cross-sensitivity between beta-lactam antibiotics

Urine Glucose Test

• May cause false positive result

Galactose Intolerance

• Contains lactose, caution in patients with galactose intolerance

Hereditary Lactase Deficiency

• Contains lactose, caution in patients with Lapp lactase deficiency

Glucose-Galactose Malabsorption

• Contains lactose, caution in patients with glucose-galactose malabsorption

Haemodialysis Recommendations

• Specific doses recommended for patients on chronic, intermittent haemodialysis

Rheumatic Fever Prevention

• Treatment should continue for at least 10 days to reduce possibility of rheumatic fever

Bacteriological Monitoring

• Required for chronic urinary tract infections

Dispensing Regulation

• To be dispensed only on prescription

Colour Variability

• Reconstituted solutions may vary in colour but do not affect potency

Children's Dosage Limitation

• Paediatric dosages should not exceed those specified for adults

Related Brands

• Vecef 125 mg/1.25 ml (Pediatric Drops) - asiatic-laboratories-ltd
• Vecef-DS 250 mg/5 ml (Powder for Suspension) - asiatic-laboratories-ltd
• Vecef 125 mg/5 ml (Powder for Suspension) - asiatic-laboratories-ltd
• Vecef 500 mg (Capsule) - asiatic-laboratories-ltd
• Ultrasef 125 mg/5 ml (Powder for Suspension) - jayson-pharmaceuticals-ltd